A pharmaceutical composition for shifting a Th2 immune response to a Th1 response by natural killer T cells (NKT cells) including a therapeutically effective amount of a glycolipid of one or more of Formulas II-V or a pharmaceutically acceptable salt thereof, and a pharmaceutical carrier is provided.